SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

US FDA completes inspection at Aurobindo Pharma’s Telangana manufacturing facility

30 Sep 2023 Evaluate

The United States Food and Drug Administration (US FDA) has concluded inspection at Aurobindo Pharma’s Unit VI - B, a Formulation manufacturing facility, situated at Sangareddy District, Telangana. US FDA has conducted inspection from September 22 to September 29, 2023. At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1378.70 -6.95 (-0.50%)
20-Apr-2026 09:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.00
Dr. Reddys Lab 1233.90
Cipla 1241.30
Zydus Lifesciences 947.00
Lupin 2328.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×